ANTIPLATELET THERAPY WITH CLOPIDOGREL TAKING INTO ACCOUNT CYP2C19 GENETIC POLYMORPHISMS IN PATIENTS WITH CORONARY HEART DISEASE AFTER CORONARY ARTERY STENTING

被引：1
|
作者：
Uzokov, J. [1 ]
Alyavi, B. [2 ]
Abdullaev, A. [1 ]
Muxitdinova, O. [2 ]
Ubaydullaeva, Z. [1 ]
机构：
[1] Republican Specialized Sci Pact Med Ctr Therapy &, Cardiol, Tashkent, Uzbekistan
[2] Tashkent Pediat Med Inst, Cardiol, Tashkent, Uzbekistan
来源：
ATHEROSCLEROSIS | 2021年 / 331卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P652
引用
收藏
页码：E265 / E265
页数：1
相关论文
共 50 条
  • [31] IMPACT OF CLOPIDOGREL PLASMATIC LEVELS, CYP2C19 POLYMORPHISMS AND DRUG-DRUG INTERACTIONS ON CLINICAL OUTCOME IN CORONARY ARTERY DISEASE PATIENTS
    Abdelhedi, Rania
    Kharrat, Najla
    Maurer, Martin
    Abdelmoula, Nouha Bouayed
    Abid, Leila
    Laroussi, Lobna
    Kammoun, Samir
    Rebai, Tarek
    Rebai, Ahmed
    Silvestro, Luigi
    FARMACIA, 2018, 66 (01) : 135 - 148
  • [32] STUDY ON THE ASSOCIATION BETWEEN CLOPIDOGREL RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND CYP2C19 POLYMORPHISMS
    Geng, Wang Tian
    Heng, Cao
    HEART, 2011, 97 : A111 - A111
  • [33] The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study
    Saydam, Faruk
    Degirmenci, Irfan
    Birdane, Alparslan
    Ozdemir, Mahmut
    Ulus, Taner
    Ozbayer, Cansu
    Colak, Ertugrul
    Ata, Necmi
    Gunes, Hasan Veysi
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 (01) : 29 - 36
  • [34] Association of CYP2C19 Polymorphisms and Proton-pump Inhibitors (PPI) with Efficacy of Clopidogrel in Patients with Coronary Atherosclerotic Heart Disease (CHD)
    Zhu, Q.
    Chen, X. Y.
    Wang, G. F.
    Lu, Y. D.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2013, 61 : S348 - S348
  • [35] The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients
    Amin, Arwa M.
    Chin, Lim Sheau
    Noor, Dzul Azri Mohamed
    Mostafa, Hamza
    Kader, Muhamad Ali S. K. Abdul
    Hay, Yuen Kah
    Ibrahim, Baharudin
    THROMBOSIS RESEARCH, 2017, 158 : 22 - 24
  • [36] Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention
    Desai, Nihar R.
    Canestaro, William J.
    Kyrychenko, Pavlo
    Chaplin, Donald
    Martell, Lori A.
    Brennan, Troyen
    Matlin, Olga S.
    Choudhry, Niteesh K.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2013, 6 (06): : 694 - +
  • [37] IMPACT OF THE CYP3A4 METABOLIC ACTIVITY AND CYP2C19 POLYMORPHISMS ON ANTIPLATELET EFFECTS OF CLOPIDOGREL IN RUSSIAN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING CORONARY STENT IMPLANTATION
    Mirzaev, K. B.
    Sychev, D. A.
    Andreev, D. A.
    Kazakov, R. E.
    Smirnov, V. V.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E78 - E78
  • [38] Differential impact of omeprazole, pantoprazole and CYP2C19 on clopidogrel pharmacokinetics and pharmacodynamics in stable coronary artery disease patients
    Collet, J. -P
    Simon, N.
    Finzi, J.
    Cayla, C.
    Silvain, J.
    Montalescot, G.
    Hulot, J. S.
    EUROPEAN HEART JOURNAL, 2012, 33 : 321 - 322
  • [39] The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel
    Tousoulis, Dimitris
    Siasos, Gerasimos
    Zaromitidou, Marina
    Oikonomou, Evangelos
    Maniatis, Konstantinos
    Kioufis, Stamatios
    Kokkou, Eleni
    Papavassiliou, Athanasios G.
    Stefanadis, Christodoulos
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (02) : 1594 - 1596
  • [40] The effect of loss-of-function allele (CYP2C19*3) with Clopidogrel efficacy in coronary heart disease patients
    Rochmawati, Ike Dhiah
    Hidayat, Nur
    Pomantow, David
    PHARMACY EDUCATION, 2021, 21 (02): : 178 - 183
12345